EA201070400A1 - Фактор, вовлеченный в латентную инфекцию герпес-вирусом, и его применение - Google Patents

Фактор, вовлеченный в латентную инфекцию герпес-вирусом, и его применение

Info

Publication number
EA201070400A1
EA201070400A1 EA201070400A EA201070400A EA201070400A1 EA 201070400 A1 EA201070400 A1 EA 201070400A1 EA 201070400 A EA201070400 A EA 201070400A EA 201070400 A EA201070400 A EA 201070400A EA 201070400 A1 EA201070400 A1 EA 201070400A1
Authority
EA
Eurasian Patent Office
Prior art keywords
factor
involved
mental
application
herpes virus
Prior art date
Application number
EA201070400A
Other languages
English (en)
Other versions
EA023557B1 (ru
Inventor
Казухиро Кондо
Нобуюки Кобаяси
Original Assignee
Джапан Тобакко Инк.
Вайрус Икагаку Кенкюсо Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джапан Тобакко Инк., Вайрус Икагаку Кенкюсо Инк. filed Critical Джапан Тобакко Инк.
Publication of EA201070400A1 publication Critical patent/EA201070400A1/ru
Publication of EA023557B1 publication Critical patent/EA023557B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C12N2710/16522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C12N2710/16571—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/035—Herpes simplex virus I or II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Описаны белок и ген, каждый из которых является фактором, вовлеченным в латентную инфекцию герпес-вирусом. Антитело против фактора детектируют приблизительно у 50% пациентов, страдающих ментальными нарушениями, в то время как антитело почти невозможно детектировать у здоровых индивидов. Кроме того, у мышей с введенным им SITH-1 развивается ментальное нарушение, такое как маниакально-депрессивное заболевание или подобное депрессии нарушение. На основании этих открытий становится возможным предоставление способа объективного определения ментального нарушения и животной модели ментального нарушения.
EA201070400A 2007-09-27 2008-09-25 Белок, вовлеченный в латентную инфекцию герпесвирусом, и его применение для диагностики ментальных нарушений у животных EA023557B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007250461 2007-09-27
PCT/JP2008/067300 WO2009041501A1 (ja) 2007-09-27 2008-09-25 ヘルペスウイルスの潜伏感染に関与する因子及びその利用

Publications (2)

Publication Number Publication Date
EA201070400A1 true EA201070400A1 (ru) 2010-10-29
EA023557B1 EA023557B1 (ru) 2016-06-30

Family

ID=40511384

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070400A EA023557B1 (ru) 2007-09-27 2008-09-25 Белок, вовлеченный в латентную инфекцию герпесвирусом, и его применение для диагностики ментальных нарушений у животных

Country Status (15)

Country Link
US (5) US8431352B2 (ru)
EP (2) EP2199391B1 (ru)
JP (4) JP4920084B2 (ru)
KR (1) KR101655486B1 (ru)
CN (1) CN101809153B (ru)
AU (1) AU2008304896B9 (ru)
CA (1) CA2701668C (ru)
EA (1) EA023557B1 (ru)
ES (1) ES2554340T3 (ru)
IL (2) IL204641A (ru)
MX (1) MX2010003318A (ru)
NZ (2) NZ584642A (ru)
UA (1) UA101814C2 (ru)
WO (1) WO2009041501A1 (ru)
ZA (1) ZA201002424B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2199391B1 (en) 2007-09-27 2015-11-11 Japan Tobacco, Inc. Factor involved in latent infection with herpesvirus, and use thereof
US9657324B1 (en) 2008-10-03 2017-05-23 Virus Ikagaku Kenkyusho Inc. Method for treating or preventing mood disorders
SG174558A1 (en) * 2009-03-31 2011-10-28 Japan Tobacco Inc Method for detecting substance in biological sample
BRPI1015458A2 (pt) * 2009-03-31 2016-04-19 Japan Tobacco Inc método para detectar anticorpo contra sith-1 em amostra biológica
EP3058105B1 (en) * 2013-10-18 2019-05-22 Seegene, Inc. Detection of target nucleic acid sequence on solid phase by pto cleavage and extension using hcto assay
JP6608818B2 (ja) 2014-06-27 2019-11-20 日本たばこ産業株式会社 気分障害を診断、治療又は予防する方法
WO2016031581A1 (ja) * 2014-08-27 2016-03-03 株式会社ウイルス医科学研究所 疲労に関与する因子及びその利用
JP6641387B2 (ja) * 2015-12-28 2020-02-05 日本たばこ産業株式会社 融合タンパク質及びその利用
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
CN109376816B (zh) * 2018-09-11 2022-04-01 广州金域医学检验中心有限公司 一种病理切片质量监控方法及其装置
WO2020202923A1 (ja) 2019-03-29 2020-10-08 日本たばこ産業株式会社 うつ病の評価方法及びうつ病の治療法の効果の評価方法、並びにうつ病若しくはうつ病の治療法の効果を評価するためのデータ取得方法
JP2024065869A (ja) 2022-10-31 2024-05-15 株式会社荏原製作所 基板処理装置、基板処理方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US823975A (en) 1905-08-07 1906-06-19 Harry B Smith Device for filling fountain-pens.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co MICROORGANISM PRODUCING TRYPTOPHANE.
LU86128A1 (fr) 1985-10-18 1987-06-02 Vander Poorten Henri Procede permettant l'impression ou le revetement de ceramique simultanement a son electroformage et conduisant en monocuisson a des produits decoratifs ou techniques
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
DE3901857A1 (de) 1989-01-23 1990-07-26 Boehringer Mannheim Gmbh Verfahren zur bestimmung von hiv 2 antikoerpern
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
GB9303157D0 (en) 1993-02-17 1993-03-31 Scotia Holdings Plc Treatment of a group of related disorders
JP3206311B2 (ja) 1994-07-29 2001-09-10 富士レビオ株式会社 抗体検出用試薬の非特異反応吸収剤
JP3517031B2 (ja) 1995-06-09 2004-04-05 日清紡績株式会社 生物学的活性物質の分析法
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
JPH11196870A (ja) 1998-01-08 1999-07-27 Katsuhiko Mikoshiba 受容体の機能解析法及びリガンド分子のスクリーニング法
ES2392247T3 (es) 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
MEP32508A (en) 2002-09-06 2010-10-10 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
JP2004301646A (ja) 2003-03-31 2004-10-28 Sysmex Corp 免疫検査用非特異反応吸収剤
US8642045B2 (en) 2003-08-29 2014-02-04 Virus Ikagaku Kenkyusho Inc. Recombinant virus vector originating in HHV-6 or HHV-7, method of producing the same, method of transforming host cell using the same, host cell transformed thereby and gene therapy method using the same
WO2006006634A1 (ja) * 2004-07-14 2006-01-19 Virus Ikagaku Kenkyusho Inc. 疲労度評価方法およびその利用
US20090068253A1 (en) 2005-09-06 2009-03-12 Guilford F Timothy Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione
WO2008057366A2 (en) 2006-11-01 2008-05-15 Beckman Coulter, Inc. Binding surfaces for affinity assays
US20080227111A1 (en) 2007-03-16 2008-09-18 Sysmex Corporation Reagent kit and method for measuring hcv antibody
JP4975601B2 (ja) 2007-03-16 2012-07-11 シスメックス株式会社 Ｈｃｖ抗体測定用試薬キット及びｈｃｖ抗体測定方法
WO2009006312A1 (en) 2007-07-03 2009-01-08 One Lambda Methods of detecting antibodies specific for denatured hla antigens
BRPI0816103A2 (pt) 2007-08-28 2020-08-18 Japan Tobacco Inc. método para ligar proteínas a carregadores por fazer uso de tamavidinas.
EP2199391B1 (en) 2007-09-27 2015-11-11 Japan Tobacco, Inc. Factor involved in latent infection with herpesvirus, and use thereof
US20110053145A1 (en) 2008-03-31 2011-03-03 Japan Tobacco Inc. Quantitation method of virus
US20110166106A1 (en) 2008-06-17 2011-07-07 Manfred Marschall Artemisinin and derivatives thereof as antivirals
US20120064543A1 (en) 2009-03-02 2012-03-15 Virus Ikagaku Kenkyusho Inc. Method for detecting substance in biological sample
BRPI1015458A2 (pt) 2009-03-31 2016-04-19 Japan Tobacco Inc método para detectar anticorpo contra sith-1 em amostra biológica
SG174558A1 (en) 2009-03-31 2011-10-28 Japan Tobacco Inc Method for detecting substance in biological sample
JP2013150553A (ja) 2012-01-24 2013-08-08 Osaka Bioscience Institute ＣａｒｔｐｔｍＲＮＡ発現細胞標識動物およびそれを用いたスクリーニング方法
JP2014019658A (ja) 2012-07-13 2014-02-03 Hiroshima Univ 抗−ｓ９７７リン酸化ｐｅｒ２特異的抗体
JP6608818B2 (ja) 2014-06-27 2019-11-20 日本たばこ産業株式会社 気分障害を診断、治療又は予防する方法

Also Published As

Publication number Publication date
EP2987859A1 (en) 2016-02-24
US10487118B2 (en) 2019-11-26
NZ599590A (en) 2013-12-20
US20100281550A1 (en) 2010-11-04
EP2199391A1 (en) 2010-06-23
JP4920084B2 (ja) 2012-04-18
EP2199391A4 (en) 2011-01-19
IL219541A0 (en) 2012-06-28
AU2008304896A2 (en) 2010-05-27
US20200071363A1 (en) 2020-03-05
EP2987859B1 (en) 2018-08-08
JP5337232B2 (ja) 2013-11-06
JP2012110329A (ja) 2012-06-14
AU2008304896A1 (en) 2009-04-02
JP5829228B2 (ja) 2015-12-09
US20130217044A1 (en) 2013-08-22
CA2701668C (en) 2017-07-11
CN101809153A (zh) 2010-08-18
AU2008304896B2 (en) 2014-07-31
US20170190745A1 (en) 2017-07-06
ZA201002424B (en) 2011-02-23
AU2008304896B9 (en) 2014-12-18
US8431352B2 (en) 2013-04-30
CA2701668A1 (en) 2009-04-02
IL204641A (en) 2013-08-29
JP2013188210A (ja) 2013-09-26
KR20100074191A (ko) 2010-07-01
IL204641A0 (en) 2010-11-30
JP2016006435A (ja) 2016-01-14
EA023557B1 (ru) 2016-06-30
UA101814C2 (ru) 2013-05-13
JPWO2009041501A1 (ja) 2011-01-27
EP2199391B1 (en) 2015-11-11
ES2554340T3 (es) 2015-12-18
NZ584642A (en) 2012-08-31
WO2009041501A1 (ja) 2009-04-02
US10526374B2 (en) 2020-01-07
US20130137088A1 (en) 2013-05-30
CN101809153B (zh) 2014-01-01
KR101655486B1 (ko) 2016-09-07
MX2010003318A (es) 2010-04-09

Similar Documents

Publication Publication Date Title
EA201070400A1 (ru) Фактор, вовлеченный в латентную инфекцию герпес-вирусом, и его применение
CY1118377T1 (el) Syk αναστολεις ιμιδαζοπυραζινης
Lally et al. Understanding frailty
Veeranki et al. Defective homocysteine metabolism: potential implications for skeletal muscle malfunction
Woodman et al. Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-β1
Su et al. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
Risser et al. Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain
Somervaille et al. Safety, phamacokinetics (PK), pharmacodynamics (PD) and preliminary activity in acute leukemia of Ory-1001, a first-in-class inhibitor of lysine-specific histone demethylase 1A (LSD1/KDM1A): initial results from a first-in-human phase 1 study
DK2114990T5 (da) Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor
EA201300125A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний желудочно-кишечного тракта функциональной этиологии
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
Savage et al. Defining pre-clinical psoriatic arthritis in an integrated dermato-rheumatology environment
Atlas et al. Sustained elevation of kynurenic acid in the cerebrospinal fluid of patients with herpes simplex virus type 1 encephalitis
Lee et al. Association between blood pressure, blood pressure variability, and post-stroke cognitive impairment
WO2008074029A3 (en) Protein profile for osteoarthritis
Jakobsson et al. Potential physiological and cellular mechanisms of exercise that decrease the risk of severe complications and mortality following SARS-CoV-2 infection
Antioch et al. Preclinical considerations about affective disorders and pain: a broadly intertwined, yet often under-explored, relationship having major clinical implications
Schlabe et al. Moderate endurance training (marathon-training)–effects on immunologic and metabolic parameters in HIV-infected patients: the 42 KM cologne project
Coresh et al. A stable definition of chronic kidney disease improves knowledge and patient care
Zheng et al. Epigenetic Reader Bromodomain-Containing Protein 4 in Aging-Related Vascular Pathologies and Diseases: Molecular Basis, Functional Relevance, and Clinical Potential
Keilich et al. Vaccination mitigates influenza-induced muscular declines in aged mice
MX2014002144A (es) Metodo para predecir el beneficio clinico del tratamiento de los transtornos del desarrollo neurologico, neurologicos o neuropsiquiatricos.
BR112014019274A2 (pt) métodos relacionados ao tratamento de doenças e distúrbios inflamatórios
Bilenberg et al. Prescription rates of ADHD medication in the Scandinavian countries and their national guidelines

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU